Thrivent Financial for Lutherans lowered its holdings in shares of Dolby Laboratories (NYSE:DLB – Free Report) by 49.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,355 shares of the electronics maker’s stock after selling 33,637 shares during the period. Thrivent Financial for Lutherans’ holdings in Dolby Laboratories were worth $2,486,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in DLB. Royal Bank of Canada boosted its holdings in shares of Dolby Laboratories by 3.5% during the 1st quarter. Royal Bank of Canada now owns 68,367 shares of the electronics maker’s stock worth $5,491,000 after buying an additional 2,298 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Dolby Laboratories by 218.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 249,574 shares of the electronics maker’s stock valued at $20,043,000 after acquiring an additional 171,288 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Dolby Laboratories by 5.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 238,216 shares of the electronics maker’s stock valued at $19,131,000 after acquiring an additional 12,598 shares during the period. Focus Partners Wealth bought a new position in Dolby Laboratories during the first quarter worth $390,000. Finally, Ameritas Advisory Services LLC acquired a new stake in Dolby Laboratories in the second quarter worth $48,000. 58.56% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In related news, CEO Kevin J. Yeaman sold 36,699 shares of Dolby Laboratories stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $66.91, for a total transaction of $2,455,530.09. Following the transaction, the chief executive officer owned 114,725 shares of the company’s stock, valued at $7,676,249.75. The trade was a 24.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Mark Andrew Sherman sold 9,109 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $66.73, for a total value of $607,843.57. Following the sale, the executive vice president owned 73,054 shares of the company’s stock, valued at $4,874,893.42. This trade represents a 11.09% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 137,120 shares of company stock worth $9,184,809 over the last three months. Company insiders own 37.93% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on DLB
Dolby Laboratories Price Performance
Shares of NYSE DLB opened at $68.15 on Wednesday. The company has a 50-day moving average price of $64.76 and a 200-day moving average price of $68.24. The stock has a market capitalization of $6.51 billion, a P/E ratio of 27.48 and a beta of 0.86. Dolby Laboratories has a 1 year low of $60.14 and a 1 year high of $85.21.
Dolby Laboratories (NYSE:DLB – Get Free Report) last posted its earnings results on Thursday, January 29th. The electronics maker reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.07. Dolby Laboratories had a net margin of 17.97% and a return on equity of 11.50%. The company had revenue of $346.71 million for the quarter, compared to analyst estimates of $341.26 million. During the same quarter in the prior year, the business posted $1.14 EPS. The firm’s revenue was down 2.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Dolby Laboratories will post 2.94 earnings per share for the current fiscal year.
Dolby Laboratories Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 18th. Stockholders of record on Tuesday, February 10th will be issued a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, February 10th. Dolby Laboratories’s dividend payout ratio (DPR) is currently 58.06%.
About Dolby Laboratories
Dolby Laboratories, Inc is a global leader in audio and imaging technologies, specializing in the development, licensing and deployment of solutions that enhance entertainment and communications experiences. The company’s core business revolves around creating advanced audio codecs, noise reduction systems and spatial sound technologies for a wide range of applications, including cinema, broadcast, gaming, streaming and personal devices. Dolby’s licensing model enables consumer electronics manufacturers, content creators and service providers to integrate its technologies into products such as televisions, smartphones, home theater systems and set-top boxes.
Among its flagship innovations are Dolby Atmos, an immersive audio format that delivers three-dimensional soundscapes for theaters and home systems; Dolby Digital and Dolby Digital Plus, widely adopted audio compression formats for broadcast and streaming; and Dolby Vision, a high-dynamic-range imaging technology that expands color, contrast and brightness in displays.
Featured Articles
- Five stocks we like better than Dolby Laboratories
- Nvidia CEO Issues Bold Tesla Call
- Your Bank Account Is No Longer Safe
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
Want to see what other hedge funds are holding DLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dolby Laboratories (NYSE:DLB – Free Report).
Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
